Labcorp To Acquire Select Assets of MAWD Pathology Group

BURLINGTON, N.C., (Dec. 16, 2024) — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has entered into an agreement with MAWD Pathology Group in Lenexa, Kansas, to acquire select assets of the independent laboratory’s clinical and women’s health testing businesses.

The Future of Lab Medicine

 

Tune in as Dr. Mahul Amin discusses the evolving landscape of diagnostic testing, the impact of lab medicine on health systems, and future innovations that promise to shape the field, providing valuable insights for healthcare leaders.

Labcorp Finalizes Acquisition of Select Outreach Services From Ballad Health

JOHNSON CITY, Tenn. and BURLINGTON, NC, (Dec. 11, 2024) - Labcorp, a global leader of innovative and comprehensive laboratory services, announces it has finalized its acquisition of select outreach laboratory services from Ballad Health. 

Simplifying and advancing workplace drug testing with oral fluid

The landscape of workplace drug testing is evolving, with oral fluid testing at the forefront of this evolution. As the U.S. Department of Transportation (DOT) and other federal agencies approve an oral drug test for regulated programs, employers will soon have a new tool at their disposal for maintaining safe and drug-free workplaces. Here’s what you need to know.

Julia Wang

Julia Wang has served as Executive Vice President and Chief Financial Officer of Labcorp since December 2024.

Prior to joining Labcorp, Julia served as CFO of BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) since 2021, which she joined in 2020 as Senior Vice President, Enterprise Optimization and Deputy CFO. While at BeiGene, she was instrumental in driving business transformations through accelerating growth, nurturing innovation and cultivating a culture of sustainable operating efficiencies.

Manuscript: Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1

Investigators from Illumina and Labcorp medical affairs teamed up to perform the largest real-world characterization of advanced non-small cell lung cancer using the TruSight® Oncology 500 (TSO500) assay to date. In our recently published manuscript in Frontiers, we assessed the spectrum of current FDA therapy-associated and clinical trial-associated genomic variants, along with known and novel patterns of co-mutations and co-occurrence with biomarkers predictive of immunotherapy response. We retrospectively analyzed clinical TSO 500 testing data from 7,606 NSCLC  biopsy specimens submitted for testing during standard clinical care. Our data provides further characterization of NSCLC at the genomic and immune checkpoint inhibitor response biomarker level and highlights the clinical utility of broad coverage CGP testing in detecting both known and novel facets of NSCLC to inform treatment decision-making. 

Molecular Tumor Board: 82-year-old female with high grade ovarian serous adenocarcinoma and BRCA1 F709fs mutation

An 82-year-old with advanced high-grade serous ovarian cancer and a BRCA1 mutation highlights the importance of somatic and germline testing to guide therapy and using PARP inhibitors for maintenance. Join our Molecular Tumor Board to explore treatment strategies and the impact of reversion mutations on resistance management.

Graphical Summary: Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer

Ask the expert: What you need to know about working with a genetic counselor

Have questions about family genetic health risks or reproductive genetic risks? Genetic counseling can help. Learn more about what genetic counselors do.

Multiple sclerosis monitoring profile

Blood biomarkers (BBMs) are a new frontier in neurology, impacting the way physicians diagnose, manage and monitor neurodegenerative diseases such as Alzheimer’s and ALS. The promise of BBMs, particularly neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), to change and improve multiple sclerosis (MS) patient management is now being realized.